Do race, ethnicity and ancestry still impact HLA genotyping?
Race, ethnicity and ancestry. How are they different? And, as testing and cell therapy science evolves, do they still impact HLA genotyping? That was the focus of discussion
Race, ethnicity and ancestry. How are they different? And, as testing and cell therapy science evolves, do they still impact HLA genotyping? That was the focus of discussion
Many allogeneic cell therapy developers believe they can overcome HLA barriers. However, HLA is only one factor to consider, and the issue of histocompatibility should not be overlooked.
Allogeneic cell therapy development has been top-of-mind in recent years as autologous cell therapies see continued success. For more than three decades, the largest group of HLA experts in the world has worked to create a unique cell source selection expertise. That expertise holds value for allogeneic cell and gene therapy developers, too.
Allogeneic cell therapies are inherently complex. But they also hold the potential to scale to treat large segments of the population. Martin Maiers, MS, is the Vice President of Innovation at the National Marrow Donor Program® (NMDP)/Be The Match®. He and his team develop software and analytical methods used to predict factors that can impact…
The emergence of novel cell therapy technologies has led to questions about the necessity of human leukocyte antigen matching (HLA matching) in the development of potential “universal” allogeneic cell therapies. After all, if you can eliminate alloreactive responses, what role would HLA matching play? Martin Maiers, MS, is the Vice President of Biomedical Informatics for…
Since its debut in 2012, CRISPR-based gene editing has taken the scientific world by storm. From disease modeling to prenatal screening, the innovative platform has been hyped and hailed as the ultimate scientific multi-tool—capable of revolutionizing the treatment of human disease. In the flood of headlines and hyperbole, it can often be hard to determine…